ClinicalTrials.gg
CompletedNCT02364882Updated Jun 22, 2015

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

A Phase 1 interventional study of Sildenafil in Female Sexual Health, sponsored by Strategic Science & Technologies, LLC. Completed at 1 site in United States. Open to female participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by Strategic Science & Technologies, LLC · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
35 Years to 65 Years
Sex
Female
01

Study summary

This is a Phase 1, single center, open-label, within-subject dose-escalation study evaluating the safety and pharmacokinetics of SST-6006 in healthy postmenopausal women. Three dose levels of SST-6006 and a placebo regimen will be evaluated: 1 g (0 mg of sildenafil), 1 g (50 mg of sildenafil), 2 g (100 mg of sildenafil), and 4 g (200 mg of sildenafil). Doses will be administered sequentially and will be separated by a 14-16 day washout period. All 3 dose levels and the placebo will be applied both externally and internally.

Read the detailed description

Subject eligibility will be determined through Screening evaluations. Screening evaluations will include a review of inclusion and exclusion criteria, medical and Ob-Gyn history; full physical and gynecological examinations (including vulvar-vaginal examination); Pap smear; vital signs (supine); orthostatic blood pressure and heart rate; laboratory assessments (chemistry, hematology, prothrombin time, FSH and urinalysis); concomitant medication use; electrocardiogram (ECG); serology for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, sexually transmitted infection (syphilis, gonorrhea, chlamydia), Herpes (HSV-2) and human immunodeficiency virus (HIV) antibodies; and urine drug screen. The Screening visit will occur up to 28 days before Day 1.

For each dose level, safety from the first 2 subjects dosed will be evaluated prior to dosing the remainder of subjects at that dose level. If results indicate safety issues (defined as a known occurrence of an event of orthostatic hypotension (up to 8 hours post dose) and/or any score above 0 using the 4 point Vulvar-vaginal Irritation Scale in the first 2 subjects, an additional 2 subjects will be dosed and safety data evaluated. If no additional safety problems are found, the remaining subjects will be dosed at that level. If safety issues are found in the second 2 subjects dosed, no further dosing will occur and the prior dose level will be considered the maximum tolerated dose. In addition, any subject who experiences orthostatic hypotension at any point in the study or has a vulvar-vaginal irritation score above a 0 using the 4 point Vulvar-vaginal Irritation Scale at any dosing level will be withdrawn from the study and not proceed to the next level. An additional review of the safety data upon completion of dosing at each level will be done to determine if dose escalation is warranted. Safety decisions will be made by the Principal Investigator (PI) and the Medical Monitor based on their clinical judgment.

The first day of dosing will be considered Day 1. Subjects will be housed in the clinic for the duration of each Treatment Period to allow for collection of the PK samples up to 32 hours post-dose and the completion of all discharge procedures.

02

Conditions studied

  • Female Sexual Health
03

In context

Lead sponsor

Strategic Science & Technologies, LLC is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be (surgically induced or natural) between the ages of 35 and 65 years, inclusive, verified by 1 of the following:

    • Surgical oophorectomy, partial hysterectomy, or full hysterectomy at least 1 year prior to screening (self-report).
    • No spontaneous menses > 1 year (self-report).
  2. Subject must have a serum follicle-stimulating hormone (FSH) lab result > 40mIU/mL.
  3. Subject has a (BMI) from 18 to 33 kg/m², inclusive.
  4. Subject has a normal at baseline.
  5. Subject has had a Pap smear performed within one year prior to the Screening visit and can provide documentation indicating normal test results.

    • If the subject cannot provide documentation, a Pap smear will be performed at Screening. Subjects with abnormal findings will be excluded from study participation and be referred for follow-up medical care as appropriate.
  6. Subject is in good health for age, as determined by medical and Ob-Gyn history and physical and gynecological examinations.

    • As part of the gynecological exam the subject must have a pain intensity score of 0 with the cotton swab test in the lower vagina, labia majora, and labia minora when asked about pain intensity on the 0 -¬ 10 verbal rating scale when gently pressing cotton swab. Also with the cotton swab test to assess tenderness within the vulvar vestibule the score must be similarly 0 on the pain intensity score on the 0 ¬ 10 verbal rating scale when gently pressing the cotton swab at 2, 5, 7 and 10 o'clock position within the vulvar vestibule.
  7. Subject is a non-smoker (no tobacco use within 6 months) and agrees not to smoke for the duration of the study up until completion of the last Treatment Period.
  8. Subject is capable of understanding and complying with the protocol and agrees to sign the document.
  9. Subject agrees to abstain from sexual activity (anal, oral, or vaginal) for one week after discharge for each Treatment Period to avoid potential partner exposure to the product.
  10. Subjects must agree to not use vaginal or vulvar lubricants, spermicides, creams or gels, foams or vaginal douche products for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject has any disorder or a history of any disorder that may prevent the successful completion of the study in the opinion of the PI.
  2. Subject has a significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, genitourinary, or psychiatric disease or other unstable medical condition that would contraindicate administration of study medication, interfere with study evaluation, limit study participation, or confound the interpretation of study results in the opinion of the PI.
  3. Subject has a history of sexual or physical abuse.
  4. Subject had an active ulcer or bleeding disorder.
  5. Subject has a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to Day 1; or any history of coronary disease causing angina; or congestive heart failure requiring medical intervention.
  6. Subject has retinitis pigmentosa or sickle cell anemia or related anemias, even if the subject feels clinically well at the time of Screening. Subjects with retinitis pigmentosa will be identified by specifically asking whether they have the condition, if there are visual signs and symptoms of the condition (including questioning subjects as to whether they have difficulty seeing at night or in low light, and if they have any visual field deficits that indicate a loss of peripheral or central vision), or if there is a family history.
  7. Subject has a history of orthostatic hypotension or orthostatic hypotension which is present at the Screening visit, defined as a drop in systolic blood pressure ≥ 20 mm Hg, a drop in diastolic blood pressure ≥ 10 mm Hg or experiencing lightheadedness or dizziness at 1 or 3 minutes after the change in position from supine to standing.
  8. Subject has untreated hypertension.
  9. Subject has type 1 or type 2 diabetes.
  10. Subject has a history of cancer, other than basal cell carcinoma.
  11. Subject has any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article in the opinion of the PI.
  12. Subject has a history of drug abuse within 1 year before Day 1.
  13. Subject has a history of alcoholism within 1 year before Day 1, admitted alcohol abuse, average consumption of more than 1 standard unit of alcohol per day (a standard unit equals 12 ounces of beer, 1½ ounces of 80-proof alcohol, or 6 ounces of wine).
  14. Subjects who have a history of non-arteritic ischemic optic neuropathy (NAION)
  15. Subject has had treatment currently or within 1 month (28 days) prior to Day 1 with any of the following: weak, moderate, and strong inhibitors and inducers of and CYP2C9 enzymes (e.g., CYP3A4: ketoconazole, clarithromycin, verapamil, diltiazem, St. John's Wort / CYP2C9: fluconazole, oxandrolone, fluvastatin, and metronidazole). Any prescription, over-the-counter (OTC) medications, or herbal products taken recently or currently being taken will be screened by study personnel prior to study enrollment to confirm such drugs do not inhibit or induce the 2 enzymes listed above. If the subject takes any prescription or OTC drugs at the direction of a health care provider that are inhibitors or inducers of CYP3A4 and CYP2C9, that provider should be consulted before medications are stopped for the purposes of study participation.
  16. Subject has positive findings from the urine drug screen (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, and opiates).
  17. Subject has positive serologic findings for sexually transmitted infection (syphilis, gonorrhea, chlamydia), (HIV) antibodies, surface antigen (HBsAg), or virus (HCV) antibodies.
  18. Subject has had an active genital herpes infection (blisters or vesicles) at any time.
  19. Subject has participated in any clinical research study evaluating another drug or therapy within 30 days before Day 1 (or 6 half-lives of the investigational agent, whichever is longer).
  20. Subject has any abnormal findings on vulvar-vaginal examination performed during the physical and gynecological exams at Screening (e.g., genital skin breaks, irritation, dermatoses, or lesions).
  21. Subject is using any intravaginal or vulvar therapies, aside from study medication
  22. Subject has used any topical (e.g. vaginal) hormone replacement therapy in the past three months
  23. Subject has genital piercings or plans to get genital piercings during the study period.
  24. Subject has a vaginal infection including bacterial vaginosis (see Section 11.1.5) or a yeast infection. The diagnosis of yeast infections should be made by the PI based on the physical and gynecological exams; the objective is to exclude women that are symptomatic. If the woman is not complaining of symptoms but the PI observes discharge, than the vaginal wet mount test should also be performed to confirm a diagnosis of yeast infection.
  25. Subject has to any ingredients in the study medication or placebo (see Tables 6 and 7).

Exclusion criteria checked prior to dosing for each dosing session:

  1. Subject has consumed grapefruit, grapefruit-containing products, Seville oranges, or products containing Seville oranges (e.g., orange marmalade) within 3 days before dosing in each Treatment Period. If so they should be rescheduled.
  2. Subject has had an acute disease state (e.g., nausea, vomiting, fever, or diarrhea) within 7 days before Day 1.
  3. Subject has any abnormal findings on vulvar-vaginal examination (e.g., genital skin breaks, irritation, dermatoses or lesions).
  4. Subject must continue to not have clinical evidence of a sexually transmitted disease or a vaginal infection and must be asymptomatic of yeast and bacterial vaginosis (BV). If a subject presents with a sexually transmitted disease, vaginal, yeast or a BV infection during the study period, and the PI decides that treatment is required, the subject will be excluded for further participation in the study except if the subject has a yeast or BV infection which could be treated with Monistat one day topical treatment followed by a minimum of a two day washout for a yeast infection or 2 day oral tinidazole (i.e., Tindamax) for a BV infection. Treatment Period visits can be rescheduled to allow for treatment of yeast and BV infection.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Placebo comparator
    1

    1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal

    Drug: Sildenafil

  • Active comparator
    2

    1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal

    Drug: Sildenafil

  • Active comparator
    3

    2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal

    Drug: Sildenafil

  • Active comparator
    4

    4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal

    Drug: Sildenafil

Interventions

06

What researchers measure

Primary outcomes

  1. Vaginal Irritation

    • Occurrence of vulvar-vaginal reactions documented on the vaginal safety questionnaire By Berger Bowman rating and AEs

    Time frame: 32 hours

  2. Orthostatic Hypotension

    Vital sign measurement

    Time frame: 32 Hours

  3. Incidence of AEs

    Adverse events, including occurrence of headache, orthostatic hypotension, flushing, dyspepsia, nasal congestion, urinary tract infection, abnormal vision (chromatopsia,increased sensitivity to light, blurred vision), diarrhea, dizziness, and rash

    Time frame: 32 hours

Secondary outcomes

  1. Cmax,

    Concentration max Tmax AUC0 t AUC0-∞ Kel t1/2 Cmax Tmax AUC0 t AUC0-∞ Kel

    Time frame: 32 hours

  2. AUC

    Area under curve

    Time frame: 32 hours

  3. T 1/2

    Half life

    Time frame: 32 hours

07

Study locations

1 site
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014-3616, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2015
First posted
Feb 18, 2015
Start
Jan 2015
Primary completionActual
May 2015
CompletionActual
May 2015
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02364882
Lead sponsor
Strategic Science & Technologies, LLC
Responsible party
Sponsor
First posted
Feb 18, 2015
Start date
Jan 2015
Primary completion
May 2015
Completion
May 2015
Last update
Jun 22, 2015

Study contacts

Ken Lassseter, MD
principal investigator · CPMI

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion